These included MT-802 (Supplementary Table S2) (Ibrutinib and pomalidomide) which showed full BTK degradation in CLL cells after about 4 hours at 250 nM concentration (Buhimschi et al., 2018). This evidence concerns the gene BTK and B-cell chronic lymphocytic leukemia.